AI-based nutrition plan to help with taste changes during cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-arm pilot study evaluating a web-based AI-supported dietary system that generates individualized meal recommendations for adults with taste disorders during or after cancer therapy. Participants complete taste and eating assessments, and the AI proposes recipes and action steps to address their impairments, aiming to improve nutrition within 12 weeks. The primary goal is to determine whether the nutrition intervention is perceived as helpful by the second visit. The study collects anthropometric data, taste thresholds, and eating habits and uses scheduled cancer treatment visits for assessments and delivery of recommendations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18
* Suffering from one of the following tumor entities: Multiple myeloma or malignant tumor of the gastrointestinal tract
* Mainly oral nutrition
* Subjectively perceived tumor therapy-related taste disorder
* At least two clinical presentations planned within 12 weeks with a minimum interval of three weeks
* Ability to participate in nutritional intervention, including use of the online portal and implementation of recipe suggestions (e.g. resources and access to a kitchen), either independently or with third-party support (e.g. by relatives, outpatient care services).

Exclusion Criteria:

* Pregnancy
* Taste disorder explained by other causes (e.g. existing before therapy or COVID disease)
* Placement in an inpatient care facility

Where it's running

• Universitätsklinikum Regensburg
  Regensburg, Bavaria, Germany Recruiting
• Universitätsklinikum Würzburg
  Würzburg, Bavaria, Germany Recruiting
• LMU Klinikum
  Munich, Bavaria, Germany Completed

Study contacts

• Study coordinator: Alexander Hann, Prof. Dr. med.
• Email: Hann_A@ukw.de
• Phone: +49 931 201 45918

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 6MW5311 in adults with relapsed or refractory blood cancers

  This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.

  Recruiting Phase 1 Mabwell (Shanghai) Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT07914556

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma

  In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.

  Recruiting Phase 4 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07907211

• Exercise phenotyping before chemotherapy in newly diagnosed multiple myeloma

  This observational study tests whether some newly diagnosed multiple myeloma patients with normal resting heart function already show limited exercise capacity, and whether that limitation relates to subtle heart tissue changes and future heart-related outcomes.

  Recruiting Technical University of Munich · Munich, Bavaria · NCT07851493

• SMS text check-ins to track symptoms for people with plasma cell disorders

  This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07850284

• Cevostamab with Pomalidomide and Dexamethasone after BCMA-directed CAR T therapy in multiple myeloma

  This study tests if Cevostamab combined with pomalidomide and dexamethasone can help people with multiple myeloma who have already had CAR T therapy and several prior treatments.

  Recruiting at 5 sites Phase 2 Hoffmann-La Roche · Nuremberg, Bavaria and 4 other locations · NCT07825064

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.